1.26
1.26 (0%)
As of Apr 17, 2025
Macrogenics Inc [MGNX]
Source:
Company Overview
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.
| Country | United States |
| Headquarters | rockville, maryland |
| Phone Number | (301) 251-5172 |
| Industry | manufacturing |
| CEO | Scott Koenig |
| Website | www.macrogenics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $150 |
| Operating Profit | $-110.6 |
| Net Income | $-67 |
| Net Cash | $81.9 |
Profit Ratios
| Gross Margin | $137.7 |
| Operating Margin | -73.7 |
| Profit as % of Revenues | -205.6% |
| Profit as % of Assets | -23.9% |
| Profit as % of Stockholder Equity | -57.7% |
Management Effectiveness
| Return on Equity | -57.7% |
| Return on Assets | -25.6% |
| Turnover Ratio | 53.6% |
| EBITA | $-110.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $261.7 |
| Total Liabilities | $145.6 |
| Operating Cash Flow | $-68.4 |
| Investing Cash Flow | $149.3 |
| Financing Cash Flow | $1 |
